Patient-Focused Drug Development for Nonhealing Chronic Wounds; Public Meeting; Request fo
The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public meeting entitled "Patient-Focused Drug Development for Nonhealing Chronic Wounds." The purpose of the public meeting is to obtain patient perspectives about the impact of nonhealing chronic wounds on daily life, patient views o
| Agency | Health and Human Services Department, Food and Drug Administration |
|---|---|
| Document type | Notice |
| Published | 2026-05-29 |
| Summary | The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public meeting entitled "Patient-Focused Drug Development for Nonhealing Chronic Wounds." The purpose of the public meeting is to obtain patient perspectives about the impact of nonhealing chronic wounds on daily life, patient views on treatment approaches, factors to consider when selecting a treatment, and what they consider when determining whether to participate in a clinical trial. |
| Document number | 2026-10752 |
| Official record | https://www.federalregister.gov/documents/2026/05/29/2026-10752/patient-focused-drug-development-for-nonhealing-chronic-wounds-public-meeting-request-for-comments |